Favorable Cross-Resistance Profile of HCV-796 and Boceprevir (SCH-503034) and Enhanced Anti-Replicon Activity Mediated By Combination Treatment; R. Ralston, Monday, May 21, 11:15 a.m., Room 206
Pharmacodynamic Analysis of the Antiviral Activity of the Non-Nucleoside Polymerase Inhibitor, HCV-796, in Combination With Peginterferon Alfa-2b in Treatment-Naive Patients With Chronic HCV; E.S. Maller, Monday, May 21, 2:15 p.m., Room 206
Phase II Study of celgosivir in combination with Peginterferon alfa-2b and ribavirin in chronic hepatitis C genotype 1 nonresponder patients; K.D. Kaita, Monday, May 21, 2:45 p.m., Room 206
Schering-Plough Sponsored CME Symposium "HCV Treatment Decisions: Challenging Issues" Monday, May 21, 6:30-8:30 pm, Grand Hyatt Washington, Independence Ballroom A, 1000 H Street, NW, Washington, D.C.
This case-based symposium is designed to outline effective management strategies for patients with hepatitis C virus infection. Optimizing HCV patient outcome requires a thorough understanding of the underlying patient and disease factors that influence treatment. Clinical scenarios will be presented, and through the use of case studies, the distinguished faculty will review and discuss current data to illustrate their respective treatment decisions.
About PEGINTRON and REBETOL Combination Therapy
PEGINTRON is approved in the United States for use alone or with ribavirin (800 mg/day) for the treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alpha and who are at least 18 years of age.
Alpha interferons, including PEGINTRON, may cause or aggravate
fatal or life-threatening neuropsychiatric, autoimmune, ischemic,
and infectious disorders. Patients should be monitored closely with
periodic clinical and laboratory evaluations. Patients with
persistently severe or worsen